LG Electronics, APL Apollo Tubes among 7 mid & smallcap picks by Axis Securities for August
The brokerage views the smallcap stock with an 11% upside and an overweight rating. HCG is entering a highly margin-accretive phase, positioning its EBITDA margins
The brokerage views the smallcap stock with an 11% upside and an overweight rating. HCG is entering a highly margin-accretive phase, positioning its EBITDA margins for meaningful acceleration, driven by unlocking strong operating leverage, achieved through increased utilisation rates at existing centres and strategic new LINAC installations.
This will accelerate value creation, structurally shifting the company toward higher profitability, superior capital efficiency, and sustainable long-term growth. The brokerage expects revenue, EBITDA, and PAT to grow by 10%, 19% and 231% CAGR for FY26-28E, respectively, with EBITDA margins expanding by 200 bps to 21.3% by FY28E.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
The BriefWire